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Background: The development of hepatic cancer is tightly regulated by multiple intracellular signaling pathways.
Therefore, most currently-used anti-tumor agents, which typically target single intracellular pathway, might not always
be therapeutically effective. Additionally, long-term use of these agents probably generates drug resistance and
unacceptable adverse effects. These problems increase the necessity for the development of new chemotherapeutic
approaches. Nitidine chloride (NC), a natural benzophenanthridine alkaloid, has been shown to inhibit cancer growth
via induction of cell apoptosis and suppression of cancer angiogenesis. But the precise mechanisms of its tumorcidal
activity are not well understood.
Methods: To further elucidate the precise mechanisms of its anti-tumor activity, using a hepatic cancer mouse
xenograft model, the human hepatic cancer cell lines (HepG2, HCCLM3, Huh7), and umbilical vein endothelial cells
(HUVEC), here we evaluate the effect of NC on tumor growth in vivo and in vitro and investigated the underlying
molecular mechanisms.
Results: We found that NC treatment resulted in significant decrease in tumor volume and tumor weight respectively,
but didn’t affect body weight changes. Additionally, NC treatment dose- and time-dependently reduced the cell
viability of all three hepatic cell lines. Moreover, NC suppressed the activation of STAT3, ERK and SHH pathways; and
altered the expression of critical target genes including Bcl-2, Bax, Cyclin D1, CDK4, VEGF-A and VEGFR2. These
molecular effects resulted in the promotion of apoptosis, inhibition of cell proliferation and tumor angiogenesis.
Conclusions: Our findings suggest that NC possesses a broad range of anti-cancer activities due to its ability to affect
multiple intracellular targets, suggesting that NC could be a novel multi-potent therapeutic agent for the treatment of
hepatic cancer and other cancers.
Keywords: Nitidine chloride, Hepatic cancer, HepG2 cells, Signaling transduction pathways, Cellular proliferation and
apoptosis, Tumor angiogenesisBackground
Primary hepatic cancer or liver cancer is the sixth most
commom cancer globally and the second leading cause of
cancer-related death [1-5]. The most frequent hepatic
cancer is hepatocellular carcinoma (HCC), accounting for
approximately 75% of all primary liver cancers. Another
type of liver cancer is hepatoblastoma (HBL), which is
specifically formed by immature liver cells and primarily
develops in children. To date, chemotherapy remains one* Correspondence: pjunlab@hotmail.com
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unless otherwise stated.of the major non-surgical therapeutic approaches for pa-
tients with advanced hepatic cancer [6]. However, due to
drug resistance, systemic chemotherapy produces a disap-
pointing low response rate, ranging between 10%-15% [7].
Moreover, many currently used anti-cancer agents have
potent cytotoxic effects in normal cells [8]. These pro-
blems limit the effectiveness of current HCC chemo-
therapy, thus increasing the necessity for the development
of new chemotherapeutic approaches.
The mechanisms underlying pathogenesis and deve-
lopment of HCC are complex and heterogeneous, invol-
ving multiple cellular signaling pathways including signal
transducer and activator of transcription 3 (STAT3), Sonic
Hedgehog (SHH) and extracellular regulated protein. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vival, proliferation and angiogenesis [9]. After activation
via phosphorylation, STAT3 proteins in the cytoplasm
dimerize and translocate to the nucleus where they re-
gulate the expression of critical genes involved in cancer
progression. Constitutive activation of STAT3 is strongly
associated with cancer development and commonly sug-
gests a poor prognosis [10,11]. Aberrant activation of SHH
is highly correlated with various human cancers [12-14].
SHH signaling activation is initiated at the cell surface by
binding of SHH ligand to the transmembrane receptor
Patched (Ptc), resulting in the release of Ptc-mediated
suppression of Smoothened (Smo). Smo subsequently acti-
vates the Gli family of transcription factors that regulate
the expression of various HH target genes [15-17]. Extra-
cellularsignal regulated kinase (ERK) signaling is one of
the major cell-survival and proliferation pathways. As a
major subfamily member of Mitogen-activated protein
kinases (MAPKs), activation of ERK is regulated by a cen-
tral three-tiered kinase core consisting of MAPK kinase
kinase (e.g., Raf), MAPK kinase (e.g., MEK), and MAPK
(e.g., ERK); wherein Raf phosphorylates MEK which in
turn phosphorylates and activates ERK [18]. By altering
the levels and activities of transcription factors, activation
of ERK pathway regulates the expression of various genes
mediating cell apoptosis, proliferation and angiogenesis
[19,20]. These molecular pathways described above modu-
late the expression of key genes involved in the regulation
of cell proliferation, apoptosis, and angiogenesis and are
participants in the processes of induction, progression, and
metastasis of hepatic cancer. Thus, each serves as a poten-
tial target for novel chemotherapeutics.
Natural products have received recent interest in dis-
covery of novel anti-cancer therapeutic agents as they
have relatively few side effects and have long been used
as alternative remedies for a variety of diseases including
cancer [21,22]. Therefore, identifying naturally occurring
agents is a promising approach for anticancer treatment.
Nitidine chloride, a natural benzophenanthridine al-
kaloid, is a major active compound present in a well-
known traditional Chinese medicinal herb Zanthoxylum
nitidum (Roxb) DC. Previous studies found that NC
has antifungal, anti-inflammatory and analgesic activities
[23,24]. Recently it has been shown that NC inhibits the
growth of many human cancer cells via induction of cell
apoptosis [25]. Moreover, Chen et al. reported that NC
can suppress gastric cancer angiogenesis by inhibition of
STAT3 pathway [26], and we previously reported that
the NC is able to inhibit hepoatocellular carcinoma
growth via modulation of JAK1/STAT3 pathway [27]. In
order to further elucidate the mechanism of tumorcidal
activity of NC, in the present study we evaluated its
effect on hepatic cancer growth in vivo and in vitro, and
investigated the underlying molecular mechanisms.Methods
Materials and reagents
Nitidine Chloride (NC, purity >98%) was provided from
Institute of Sichuan Xianxin Biochemical Technology
(Sichuan, China). Matrigel was provided by Becton
Dickinson (San Jose, CA, USA). Roswell Park Memorial
Institute Medium 1640 (RPMI 1640), Dulbecco’s modi-
fied Eagle’s medium (DMEM), fetal bovine serum (FBS),
penicillin-streptomycin, trypsin-EDTA, 5,5’,6,6’-tetrachloro-
1,1’,3,3’-tetraethyl-benzimidazol-carbocyanine iodide (JC-1),
were purchased from Invitrogen (Grand Island, NY, USA).
The In Vitro Angiogenesis Assay Kit was purchased from
Millipore (Billerica, MA, USA). A fluorescein isothio-
cyanate (FITC)-conjugated annexin V apoptosis detection
kit was provided by Becton Dickinson (San Jose, CA,
USA). TUNEL assay kit (TumorTACS in situ) was pur-
chased from R&D Systems (Minneapolis, MN, USA). All
antibodies were purchased from Cell Signaling Technology
(Beverly, MA, USA). BCA Protein Assay Kit was pur-
chased from Tiangen Biotech Co., Ltd. (Beijing, China).
Cignal STAT3 Reporter (luc) Kit was obtained from
SABiosciences, QIAGEN company (Hilden, Germany). All
other chemicals, unless otherwise stated, were obtained
from Sigma-Aldrich (St. Louis, MO, USA).
Cell culture
Human hepatic cancer cell lines (HepG2, HCCLM3
and Huh7) and human umbilical vein endothelial cells
(HUVECs) were purchased from Xiangya Cell Center
(Hunan, China). HepG2 cells and HUVECs were grown in
DMEM and RPMI 1640, respectively. Both DMEM and
RPMI 1640 were supplemented with 10% (v/v) FBS,
100 units/ml penicillin, and 100 μg/ml streptomycin.
Animals
Male BALB/C athymic nude mice (with an initial body
weight of 20–22 g) were obtained from Shanghai SLAC
Laboratory Animal Co., Ltd. (Shanghai, China) and
housed under pathogen-free conditions with controlled
temperature (22°C), humidity, and a 12 hour light/dark
cycle. Food and water were given ad libitum throughout
the experiment. All animal treatments were performed
strictly in accordance with international ethical guidelines
and the National Institutes of Health Guide concerning
the Care and Use of Laboratory Animals. The experiments
were approved by the Institutional Animal Care and Use
Committee of Fujian University of Traditional Chinese
Medicine.
In vivo nude mice xenograft study
Hepatic cancer xenograft mice were produced with
HepG2 cells. The cells were grown in culture and then
detached by trypsinization, washed, and resuspended in
serum-free DMEM. Resuspended cells (5 × 106) mixed
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the right flank of mice to initiate tumor growth. At
5 days following xenograft implantation (tumor size ap-
proximately 3 mm in diameter), mice were randomized
into two groups (n = 10) and treated with 4.5 mg/kg of
NC (dissolved in saline) or saline daily by intraperitoneal
injection, 6 days a week for 18 days. Body weight and
tumor size were measured. Tumor size was determined by
measuring the major (L) and minor (W) diameter with a
caliper. The tumor volume was calculated according to
the following formula: tumor volume = π/6 × L ×W2. At
the end of the experiment, the animals were anaesthetized
and tumors were excised and weighed.
Cell viability evaluation by MTT assay
NC was dissolved in DMSO and diluted to working
concentrations with culture medium. The final concen-
tration of DMSO in the medium for all cell-based experi-
ments was 0.1%. Cells (HepG2, HCCLM3, Huh7 cells or
HUVECs) were seeded into 96-well plates at a density of
1.0 × 104 cells/well in 0.1 ml medium. 24 h later, cells were
treated with various concentrations of NC for different
time periods. After NC treatment, 10 μl MTT (5 mg/ml in
phosphate buffered saline (PBS)) were added to each well,
and the samples were incubated for an additional 4 h at
37°C. The purple-blue MTT formazan precipitate was dis-
solved in 100 μl DMSO. Absorbance was measured at
570 nm using an ELISA reader (BioTek, Model EXL800,
USA).
Colony formation assay
HepG2 cells from different treated groups were seeded
in 6-well plates with a density of 200 cells per well for
7 days. The medium was discarded and each well was
washed twice with PBS carefully. The colonies were
fixed in methanol for 20 min and then stained with
Giemsa staining solution. The number of colonies with
≥50 cells was counted and colony forming efficiency was
calculated (Percentage of colonies = Number of colonies
formed/Number of cells inoculated × 100%).
Cell cycle analysis
Cell cycle analysis was carried out by flow cytometry
using FACS analysis with propidium iodide (PI) staining.
HepG2 cells were treated with various concentrations of
NC for 24 h, harvested, adjusted to a concentration of
1 × 106 cells/ml, and fixed in 70% ethanol at 4°C over-
night. The fixed cells were washed twice with cold PBS,
and incubated for 30 min with RNase (8 μg/ml) and PI
(10 μg/ml). The fluorescent signal was detected through
the FL2 channel and the proportion of DNA in different
phases was analyzed using ModfitLT Version 3.0 (Verity
Software House, Topsham).Apoptosis detection in HepG2 cells by flow cytometry
analysis with annexin V/PI staining
After incubation with various concentrations of NC, apop-
tosis of HepG2 cells were determined by flow cytometry
using a fluorescence-activated cell sorting (FACS) caliber
(Becton Dickinson, CA, USA) and Annexin V-fluorescein
isothiocyanate (FITC)/propidium iodide (PI) kit (Becton
Dickinson). Staining was performed according to the ma-
nufacturer’s instructions. The percentage of cells in early
apoptosis was calculated by Annexin V-positivity and
PI-negativity, and the percentage of cells in late apoptosis
was calculated by Annexin V-positivity and PI-positivity.
Measurement of mitochonrial membrane potential (Δψm)
by flow cytometry analysis with JC-1 staining
JC-1 is a cationic dye that exhibits potential mito-
chondria-dependent accumulation, indicated by a fluo-
rescence emission shift from green to red, which thus
can be used as an indicator of mitochondrial potential.
In this experiment, 1×106 treated HepG2 cells were re-
suspended after trypsinization in 1 ml of medium and
incubated with 10 μg/ml of JC-1 (Invitrogen) at 37°C,
5% CO2, for 30 min. Both red and green fluorescence
emissions were analyzed by flow cytometry after JC-1
staining.
Apoptosis detection in hepatic tumor tissues by TUNEL
staining
Six tumors were randomly selected from NC-treatment or
control groups. Tumor tissues were fixed in 10% for-
maldehyde for 12 h, paraffin-embedded and then sec-
tioned into 4-μm-thick slides. Samples were analyzed by
TUNEL staining using TumorTACS in situ kit (R&D Sys-
tems). Apoptotic cells were counted as DAB-positive cells
(brown stained) at five arbitrarily selected microscopic
fields at a magnification of 400×. TUNEL-positive cells
were counted as a percentage of the total cells.
Immunohistochemistical analysis of hepatic tumor tissues
Six tumors were randomly selected from NC-treatment or
control groups. Tumor tissues were fixed in 10% formal-
dehyde for 12 h, paraffin-embedded, sectioned, and placed
on slides. The slides were subjected to antigen retrieval
and endogenous peroxidase activity was quenched with
hydrogen peroxide. Non-specific binding was blocked
with normal serum in PBS (0.1% Tween 20). Rabbit
polyclonal antibodies against Ki-67, CD31, Shh and Gli-1
(all in 1:200 dilution, Santa Cruz Biotechnology) were
used to detect the relevant proteins. The binding of the
primary antibody was demonstrated with a biotinylated
secondary antibody, horseradish peroxidase (HRP)-conju-
gated streptavidin (Dako), and diamino-benzidine (DAB)
as the chromogen. The tissues were counterstained with
diluted Harris hematoxylin. After staining, five high-
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lected in each slide. The proportion of positive cells in
each field was determined using the true color multi-
functional cell image analysis management system
(Image-Pro Plus, Media Cybernetics, USA). To control for
nonspecific staining, PBS was used to replace the primary
antibody as a negative control.
Tube formation assay of HUVECs
HUVEC tube formation was examined using the ECMa-
trix assay kit (Millipore) following the manufacturer’s in-
structions. Briefly, confluent HUVECs were harvested
and diluted (1 × 104 cells) in 50 μl of medium containing
various concentrations of NC. The harvested cells were
seeded with ECMatrix gel (1:1 v/v) into 96-well plates
and incubated for 9 h at 37°C. The cells were photo-
graphed using phase-contrast inverted microscopy at a
magnification of 100 ×.
RT-PCR analysis
Total RNA was isolated from tumor tissues (three tu-
mors were randomly selected from NC-treatment or
control groups) or HepG2 cells and HUVECs with Tri-
Zol Reagent (Invitrogen). Oligo (dT)-primed RNA (1 μg)
was reverse-transcribed with SuperScript II reverse tran-
scriptase (Promega) according to the manufacturer’s in-
structions. The obtained cDNA was used to determine
the mRNA amount of Cyclin D1, CDK4, Bcl-2, Bax,
SHH, Gli-1, VEGF and VEGFR2 by PCR with Taq DNA
polymerase (Fermentas). GAPDH was used as an in-
ternal control. Samples were analyzed by gel electro-
phoresis (1.5% agarose). The DNA bands were examined
using a Gel Documentation System (BioRad, Model Gel
Doc XR+, USA).
Western blotting analysis
Three tumors were randomly selected from NC-
treatment or control groups. Tumor tissues were ho-
mogenized in nondenaturing lysis buffer and centrifuged
at 14,000 × g for 15 min. Protein concentrations of the
clarified supernatants were determined by BCA protein
assay. HepG2 cells or HUVECs (2.5 × 105) in 5 ml
medium were seeded into 25 cm2 flasks and treated with
the indicated concentrations of NC for 24 h. Treated
cells were lysed in mammalian cell lysis buffer (M-PER,
Thermo Scientific, Rockford, IL, USA) containing prote-
ase (EMD Biosciences) and phosphatase inhibitor
(Sigma-Aldrich) cocktails, and centrifuged at 14,000 × g
for 15 min. Protein concentrations in cell lysate superna-
tants were determined by BCA protein assay. Equal
amounts of protein from each tumor or cell lysate were
resolved on 12% Tris-glycine gels and transferred onto
PVDF membranes. The membranes were blocked for
2 h with 5% nonfat dry milk and incubated with thedesired primary antibody directed against STAT3,
pSTAT3, ERK, pERK, Cyclin D1, CDK4, Bcl-2, Bax,
VEGF, VEGFR2 or β-actin (all in 1:1000 dilutions) over-
night at 4°C. Appropriate HRP-conjugated secondary
antibodies with chemiluminescence detection were used
to image the antibody-detected proteins.
Luciferase gene reporter assay
HepG cells were seeded into 96-well plates at a density of
1 × 104 cells/well in 0.1 ml complete DMEM until about
50% confluency and then continuously cultured in FBS-
and antibiotics-free medium overnight. Cells were trans-
fected with a mixture of inducible STAT3-responsive
firefly luciferase construct and constitutively expressing
Renilla luciferase construct using Lipofectamine™ LTX
with PLUS™ Reagent. 6 h after transfection the medium
was changed back into DMEM complete with FBS, peni-
cillin and streptomycin. After 24 hours of transfection,
cells were treated with various contractions of NC for 1 h
followed by IL-6 for another 24 h. Cell extracts were
prepared and analyzed using Promega Dural Luciferase
Reporter Assay System according to the manufacturer’s
instruction. The measured firefly luciferase activity was
normalized to the activity of Renilla luciferase in the
same well.
Statistical analysis
Data were presented as mean ± SD for the indicated
number of independently performed experiments. Statis-
tical analysis was carried out with Student’s t-test and
ANOVA. Differences with P < 0.05 were considered to
be statistically significant.Results and discussion
NC inhibits hepatic cancer growth in vitro and in vivo
We evaluated the in vitro anti-cancer effect of NC by
examining the viability of three human hepatic cell lines
(HepG2, HCCLM3 and Huh7) using MTT assay. As
shown in Figure 1A, treatment with NC dose- and time-
dependently reduced the viability of all three hepatic cell
lines (P < 0.05). The in vivo anti-tumor activity of NC
was evaluated by comparing the tumor weight and vo-
lume in treated and control HepG2 xenograft mice,
while its adverse effects were determined by measuring
changes in body weight. As shown in Figure 1B-D, NC
treatment resulted in 56.62% and 36.14% decrease in
tumor volume and tumor weight respectively, as com-
pared to control (P < 0.01). However, administration of
NC had no effect on body weight changes during the
course of the study (Figure 1E). Taken together, these
data suggest that NC is effective in suppressing liver
tumor growth both in vivo and in vitro, without ap-
parent signs of toxicity.
Figure 2 Effect of NC on cell proliferation in hepatic cancer xenograft mice and HepG2 cells. (A) Ki-67 assay in tumor tissues (400 ×). Data
shown are averages with S.D. (error bars) from 6 individual mouse in each group. *P < 0.01, versus controls. (B) HepG2 cell colony formation assay.
The data were normalized to the viability or survival of control cells (100%, treated with 0.1% DMSO vehicle). (C) HepG2 cell cycle was analyzed
by FACS and the proportion of cells in S-phase was calculated. Data from panels B-D are averages with S.D. (error bars) from at least three
independent experiments. *P < 0.01, versus control cells.
Figure 1 Effect of NC on hepatic cancer growth in vitro and in vivo. (A) Viability of HepG2, HCCLM3 or Huh7 cells was determined by the MTT
assay after cells were treated with the different concentrations of NC for the indicated time periods. *P< 0.05, versus control cells. (B-E) In vivo study.
After tumor development, mice were randomized into two groups (n = 10) and treated with 4.5 mg/kg of NC or saline daily by intraperitoneal
injection, 6 days a week for 18 days. Tumor volume (B), tumor weight (C) and body weight (E) were measured. (D) Representative images for tumors.
Data shown are averages with S.D. (error bars) from 10 individual mouse in each group. *P< 0.01, versus controls.
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Figure 4 Effect of NC on cell apoptosis in hepatic cancer xenograft m
shown are averages with S.D. (error bars) from 6 individual mouse in each
quantification of FACS analysis. (C) Quantitative analysis of the JC-1 red/gre
averages with S.D. (error bars) from three independent experiments. *P < 0
Figure 3 Effect of NC on the expression of Cyclin D1 and CDK4
in hepatic cancer xenograft mice and HepG2 cells. The mRNA
levels of Cyclin D1 and CDK4 in tumor tissues (A) or HepG2 cells
(B) were determined by RT-PCR. The protein expression levels of
Cyclin D1 and CDK4 in tumor tissues (C) or HepG2 cells (D) were
determined by Western blotting. GAPDH and β-actin were used as
the internal controls for the RT-PCR or Western blotting, respectively.
Images are representatives of 3 individual mouse in each group or
of three independent cell-based experiments.
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cycle arrest
Cancer cells are characterized by an uncontrolled increase
in cell proliferation; we therefore determined the prolifera-
tive activity of NC. Cell proliferation in tumor tissues was
determined via immunohistochemical staining (IHC) for
Ki-67, a proliferation marker that is specifically expressed
in proliferating cell nuclei. As shown in Figure 2A, the
percentage of Ki-67 positive cells in tumor tissues from
control and NC-treated xenograft mice was 37.3 ± 8.3%
and 19.5 ± 4.0%, respectively (P < 0.01). The in vitro pro-
liferation of HepG2 cells was determined by colony forma-
tion assay. As shown in Figure 2B, treatment with 2.5, 25
and 50 μM of NC for 24 h reduced the cell survival rate
by 50%, 93% and 99% compared to untreated control cells
(P < 0.01). Thus, NC can inhibit hepatic cancer cell pro-
liferation both in vivo and in vitro.
Eukaryotic cell proliferation is primarily regulated by
cell cycle. G1/S transition is one of the major cell cycle
checkpoints [28], which is responsible for initiation and
completion of DNA replication. G1/S progression is
strongly regulated by Cyclin D1 that exerts its function via
forming an active complex with its CDK major catalytic
partners (CDK4/6) [29]. An unchecked or hyperactivated
Cyclin D1/CDK4 complex often leads to uncontrolled cell
division and malignancy [30-32]. The effect of NC on the
G1 to S progression in HepG2 cells was investigated via PI
staining followed by FACS analysis. We found that theice and HepG2 cells. (A) TUNEL assay in tumor tissues (400 ×). Data
group. *P < 0.01, versus controls. (B) Apoptosis of HepG2 cells were
en fluorescent intensity ratio. The data from C and E shown are
.05, versus controls.
Figure 6 Effect of NC on angiogenesis in hepatic cancer xenograft mi
are averages with S.D. (error bars) from 6 individual mouse in each group.
MTT assay after cells were treated with the various concentrations of NC fo
of control cells (100%, treated with 0.1% DMSO vehicle). Data are averages
*P < 0.05, versus controls. (C) Tube formation assay in HUVEc (100 ×). The n
Images are representatives of three independent experiments.
Figure 5 Effect of NC on the expression of Bcl-2 and Bax in
hepatic cancer xenograft mice and HepG2 cells. The mRNA
levels of Bcl-2 and Bax in tumor tissues (A) or HepG2 cells (B) were
determined by RT-PCR. The protein expression levels of Bcl-2 and
Bax in tumor tissues (C) or HepG2 cells (D) were determined by
Western blotting. GAPDH and β-actin were used as the internal
controls for the RT-PCR or Western blotting, respectively. Images are
representatives of 3 individual mouse in each group or of three
independent cell-based experiments.
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treatment was decreased in a dose-dependent manner
(Figure 2C, P < 0.01). In addition, data from RT-PCR and
Western Blot analysis showed that NC treatment sig-
nificantly reduced the mRNA and protein levels of pro-
proliferative Cyclin D1 and CKD4 both in hepatic tumor
tissues and HepG2 cells (Figure 3). These data together
suggest that NC inhibits hepatic cancer cell proliferation
through blockade of G1-S progression and the modulation
of the expression of cell cycle-regulatory genes.
NC induces hepatic cancer cell apoptosis via activation of
the mitochondrion-dependent pathway
Apoptosis is crucial for animal development and tissue
homeostasis. Disturbed regulation of this vital process rep-
resents a major causative factor in tumorigenesis. Promo-
ting cell apoptosis therefore has been a major focus in the
development of anti-cancer therapies. In the present study
we evaluated apoptosis in tumors via TUNEL assay; and
we found that the percentage of TUNEL-positive cells in
tumors from NC-treated mice or controls was 36.8 ± 7.1%
or 19.5 ± 3.2%, respectively (Figure 4A, P < 0.01), sug-
gesting that NC promotes cell apoptosis in tumor tis-
sues. The apoptosis of HepG2 cells was determined via
Annexin-V/PI staining followed by FACS analysis. As
shown in Figure 4B, the percent of cells undergoing eitherce and HUVECs. (A) CD31 assay in tumor tissues (400 ×). Data shown
*P < 0.01, versus controls. (B) HUVEC’s viability was determined by the
r the indicated time periods. The data were normalized to the viability
with S.D. (error bars) from at least three independent experiments.
etwork-like structures were examined by phase-contrast microscopy.
Figure 7 Effect of NC on the expression of VEGF-A and VEGFR2.
The mRNA and protein expression levels of VEGF-A and VEGFR2 in
tumor tissues (A, B) or in HepG2 cells (C, D) and HUVECs (E, F) were
determined by RT-PCR and Western Blotting. GAPDH and β-actin
were used as the internal controls for the RT-PCR or Western Blotting,
respectively. Images are representatives of 3 individual mouse in each
group or three independent cell-based experiments.
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50 μM of NC was 8.50%, 17.12% or 32.19%, whereas
the apoptotic rate in untreated control cells was 5.48%
(P < 0.05). Thus NC induces hepatic cancer cell apoptosis
in vitro in a dose-dependent manner.
The mitochondrion-dependent pathway is the most
common apoptotic pathway in vertebrate animal cells.
Mitochondrial outer membrane permeabilization (MOMP)
is a key commitment step in the induction of cellular apop-
tosis, since it is the point of convergence for a large variety
of intracellular apoptotic signaling pathways leading to the
release of many apoptogenic proteins from the mitochon-
drial intermembrane space. During the process of MOMP,
the electrochemical gradient across the mitochondrial
membrane collapses. Therefore, the loss of mitochondrial
membrane potential is a hallmark for apoptosis. To inves-
tigate the mechanism of how NC induced HepG2 cell
apoptosis, we used FACS analysis with JC-1 staining to
examine the change of mitochondrial membrane potential
in NC-treated HepG2 cells. The membrane-permeant
JC-1 dye displays potential-dependent accumulation in
mitochondria, indicated by a fluorescence emission shift
from green (~525 nm) to red (~590 nm). Therefore, col-
lapse of mitochondrial potentail during apoptosis is indi-
cated by a decrease in the ratio of red/green fluorescence
intensity. As shown in Figure 4C, after treatment with 0,
2.5, 25, 50 μM of NC the JC-1 red/green fluorescent ratio
in HepG2 cells was 6.71 ± 1.52, 2.54 ± 0.53, 1.96 ± 0.19,
1.36 ± 0.22, respectively, suggesting that NC dose-depen-
dently induces the loss of mitochondrial membrane po-
tential in HepG2 cells.
Bcl-2 family proteins are key regulators of mitochon-
drion-mediated apoptosis, functioning as either suppres-
sors such as Bcl-2, or promoters such as Bax. MOMP is
thought to occur through the formation of pores in the
mitochondria by pro-apoptotic Bax-like proteins, which
can be inhibited by anti-apoptotic Bcl-2-like members.
Therefore, the ratio of active anti- and pro-apoptotic Bcl-2
family members determines the fate of cells, and alteration
of the ratio by aberrant expression of these proteins
impairs the normal apoptotic program contributing to
various apoptosis-related diseases including cancer [33].
Higher Bcl-2 to Bax ratios are commonly found in can-
cers, which not only confers a survival advantage to the
cancer cells but also causes resistance to chemo- and
radio-therapies. To further study the mechanism of
NC’s pro-apoptotic activity, we performed RT-PCR and
Western Blotting to respectively examine the mRNA
and protein expression of Bcl-2 and Bax. As shown in
Figure 5, NC treatment significantly reduced the mRNA
and protein expression levels of anti-apoptotic Bcl-2
both in the tumor tissues and HepG2 cells, whereas
those of pro-apoptotic Bax were significantly increased
after NC treatment, suggesting that NC induces hepaticcancer cell apoptosis both in vivo and in vitro through
an increase in the pro-apoptotic Bax/Bcl-2 ratio.
NC inhibits hepatic tumor angiogenesis via suppressing
the expression of VEGF-A and VEGFR2
Formation of new blood vessels via angiogenesis is critical
for the development of solid tumors [34-37]. Initially,
tumor cells obtain oxygen and nutrients from nearby
blood vessels by simple passive diffusion. However, when
tumor grows to certain size, oxygen delivery by diffusion
is no longer sufficient, which causes tumor cells to induce
the sprouting of new blood vessels from pre-existing vas-
culature, creating a blood supply system within solid
tumor that is essential for continuous growth of tumor as
well as providing an avenue for hematogenous metastasis
[38,39]. To determine the effect of NC on angiogenesis
in vivo, we performed IHC for the expression of the endo-
thelial cell–specific marker CD31 to examine intratumoral
microvessel density (MVD). As shown in Figure 6A, the
percentage of CD31-positive cells in NC-treated mice was
significantly reduced (P < 0.01). The processes of angio-
genesis include endothelial cell (EC) proliferation, migra-
tion, and alignment into tubular structures. To further
Figure 8 Effect of NC on activation of STAT3 and ERK in
hepatic cancer xenograft mice and HepG2 cells. The level of
STAT3 or ERK phosphorylation in tumor tissues (A) and ERK
phosphorylation in HepG2 cells (B) was determined by Western blot.
β-actin was used as the internal control. Data panels from A-B are
representatives of 3 individual mouse in each group. (C) IL-6-mediated
STAT3 transcriptional activity in HepG2 cells. The transcriptional activity
of STAT3 was measured by DLR assay. Data are averages with S.D.
(error bars) from at least three independent experiments. *P < 0.05,
versus control cells; #P < 0.05, versus cells treated with IL-6 but
without NC.
Figure 9 Effect of NC on the activation of SHH pathway in hepatic ca
processed for IHC for SHH and Gli-1. The photographs are representative im
was represented as percentage of positively-stained cells. Data shown are a
*P < 0.05; **P < 0.01, versus controls. (B) The protein expression levels of Sh
β-actin was used as the internal control. The mRNA levels of SHH and Gli-1
GAPDH was used as the internal control. Images of Western Blotting and R
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http://www.biomedcentral.com/1471-2407/14/729evaluate the anti-angiogenic effect of NC we modeled
each of these processes with HUVECs in vitro. As shown
in Figure 6B, NC treatment dose- and time-dependently
decreased the proliferation (viability) of HUVECs com-
pared to untreated control cells (P < 0.05). Moreover, we
examined NC’s effect on capillary tube formation of
HUVECs using an extracellular matrix, in which cultured
ECs rapidly align and form hollow tube-like structures. As
shown in Figure 6C, untreated HUVECs formed elongated
tube-like structures, whereas NC treatment resulted in a
significant decrease in capillary tube formation. Collec-
tively, these data suggest that inhibition of tumor angio-
genesis by NC could have contributed to the inhibition of
hepatic cancer growth.
Induction of angiogenesis is mediated by a variety of
molecules released by tumor cells [40]. Vascular endothe-
lial growth factor A (VEGF-A) is considered one of the
strongest angiogenic stimulators [41]. VEGF-A is highly
expressed in a wide variety of human tumors, which has
been associated with tumor progression, invasion and me-
tastasis, and poorer survival and prognosis in patients
[42,43]. VEGF-A is secreted by tumor cells and endo-
thelial cells and functions via paracrine and autocrine sig-
naling pathways. When VEGF-A is secreted, it primarilyncer xenograft mice and HepG2 cells. (A) Tumor tissues were
ages taken at a magnification of 400 ×. Quantification of IHC assay
verages with S.D. (error bars) from 6 individual mouse in each group.
h and Gli-1 in HepG2 cells were determined by Western Blotting.
in tumor tissues (C) and HepG2 cells (D) were determined by RT-PCR.
T-PCR are representatives of 3 individual mouse in each group.
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cells (EC) [44], which in turn triggers a tyrosine kinase
signaling cascade that eventually induces angiogenesis
[44,45]. To explore the mechanism of NC’s anti-angio-
genic activity, we determined its effect on the expression
of VEGF-A and its specific receptor VEGFR2 both in vivo
and in vitro. As shown in Figure 7A and B, NC treatment
profoundly decreased mRNA and protein levels of VEGF-A
and VEGFR2 in hepatic cancer xenograft tumor tissues.
Similarly, NC dose-dependently reduced VEGF-A expres-
sion in HepG2 cells and HUVECs and also the expression
of VEGFR-2 in HUVECs, at both transcriptional and
translational levels (Figure 7C-F).
NC suppresses STAT3, ERK and SHH pathways
Cancer development is tightly regulated by multiple
intracellular signaling pathways, including STAT3, ERK
and SHH. Aberrant activation of these pathways alters
the expression of various critical target genes mediating
the processes of apoptosis, proliferation and angioge-
nesis. To further elucidate the mechanisms of anti-
tumor activity of NC, we determined its effect on the ac-
tivation of STAT3, ERK and SHH pathways. Activation
of STAT3 and ERK is mediated by its phosphorylation,
we therefore investigated STAT3 and ERK activation in
HCC tumor tissues and/or HepG2 cells by Western Blot
analysis using antibodies that recognize STAT3 or ERK
phosphorylation. As shown in Figure 8A and B, NC
treatment decreased the levels of phosphorylated STAT3
and ERK in tumors of xenograft mice and/or in HepG2
cells. The levels of non-phosphorylated STAT3 and ERK
remained unchanged. To further explore the mecha-
nisms whereby NC suppressed the activation of STAT3,
we performed Dual Luciferase Reporter assay to examine
STAT3 transcriptional activity in HepG2 cells. Results
from Figure 8C showed that NC significantly and dose-
dependently inhibited IL-6-stimulated increase of STAT3
transcriptional activity. We assessed the effect of NC on
the expression of key mediators of SHH pathway in he-
patic cancer xenograft tumors and HepG2 cells using
IHC, Western Blot and RT-PCR analyses. As shown in
Figure 9A and B, NC treatment significantly decreased
the protein expression of SHH- or Gli-1-positive cells
both in the hepatic cancer xenograft tumors and HepG2
cells. Data from RT-PCR showed that the pattern of
mRNA expression was similar to their respective protein
levels (Figure 9C and D). Taken together, these data sug-
gest that NC significantly suppresses the activation of
multiple hepatic cancer-related signaling pathways.
Conclusions
In summary, here for the first time we demonstrate that
Nitidine chloride possesses a broad range of anti-cancer
activities due to its ability to affect multiple intracellulartargets. Our findings suggest that NC could be a novel
therapeutic agent for the treatment of hepatic cancer
and other malignancies. However, it remains unclear
how NC interacts with STAT3, ERK or hedgehog sig-
naling and deactivate it, although we demonstrate these
multiple signaling pathways are affected by NC. It is un-
known whether NC is a direct transcriptional suppressor
of STAT3, ERK, SHH or Gli. In addition, the dose of NC
used in in vitro study is as high as 50 μM. The concen-
tration of NC certainly should be much lower if we try
to demonstrate its druggability in pharmaceutical re-
search. These intriguing questions must be addressed in
future studies before NC can be further developed as a
multi-target drug for cancer therapy.
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